Non-invasive assessment of lung remodelling in patients with pulmonary arterial hypertension (PAH) using [18F]-FLT PET imaging.

Non-invasive assessment of lung remodelling in patients with pulmonary arterial hypertension (PAH) using [18F]-FLT PET imaging. - Imaging the primary disease process in PAH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47690

Enrollment

Registered

2018-08-15

Start date

2017-09-11

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypetrension

Interventions

PET/CT imaging

pulmonary arterial hypertension

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1.Diagnosis of PAH, according to ESC/ERS guidelines (ref: Galie ERJ 2015) or Unaffected BMPR2 mutation carrier or Normal control subjects 2. Age >50 and

Exclusion criteria

Exclusion criteria: - Pregnant subjects - Claustrophobia - Inability to provide informed consent - In case of PAH patients: TLC

Design outcomes

Primary

Measure	Time frame
Uptake of [18F]-FLT in the lung of PAH patients.	—

Secondary

Measure	Time frame
none	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)